Yarrow Bioscience Reports Q2 2026 Financial Results with Revenue Increase and Decreased Operating Expenses

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) reported its financial results for the second quarter of 2026, revealing a total revenue of $97,000, a 40.6% increase from $69,000 in the same period last year. The company’s revenue primarily consisted of royalty income from its agreement with LEO Pharma. However, for the six months ended June 30, 2026, total revenue decreased by 32.5% to $183,000 compared to $271,000 in the prior year, reflecting a decline in royalty revenues as LEO Pharma plans to terminate its license agreement effective December 31, 2026.

The company’s operating expenses significantly decreased, totaling $3.2 million for the second quarter, down 58% from $7.6 million in the same quarter of 2025. This reduction was largely attributed to a sharp decline in research and development expenses, which fell to $788,000 from $4.9 million year-over-year. For the first half of 2026, operating expenses were $7.1 million, down from $17 million in the same period of 2025. The operating loss for the second quarter was $3.1 million, a 58.9% improvement compared to a loss of $7.5 million in the prior year. The net loss for the quarter was $3 million, compared to a loss of $5.8 million in the same quarter of 2025.

Yarrow's strategic developments included the completion of a merger with Yarrow Bioscience, which was finalized on July 27, 2026. This merger has positioned Yarrow as a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases, with its lead product candidate, YB-101, targeting Graves’ disease and thyroid eye disease. The merger was supported by a $100 million investment from institutional investors in connection with the merger agreement, which is expected to enhance the company’s financial stability and operational capabilities.

As of June 30, 2026, Yarrow reported cash and cash equivalents of $22.9 million, down from $24 million at the end of 2025. The company had no outstanding debt and an accumulated deficit of $764.2 million. The significant decrease in cash usage for operations, which was $6.1 million for the first half of 2026 compared to $22.3 million in the same period of 2025, reflects the company's efforts to streamline operations in anticipation of the merger. The company expects its existing cash resources to be sufficient to fund operations into 2028.

Looking ahead, Yarrow anticipates that the successful integration of Yarrow's business will be crucial for its growth strategy. The company plans to focus on advancing YB-101 through clinical trials and obtaining regulatory approvals. However, Yarrow also acknowledges the potential impact of macroeconomic conditions, including inflation and market volatility, on its future operations and funding requirements. The company may seek additional capital through various means, including equity or debt financing, to support its ongoing development efforts.